Surveying US observational data sources and characteristics for drug safety needs

Pharmaceutical Medicine

Volumn 24, Issue 4, 2010, Pages 231-238

  Ryan, Patrick ^a,b,c   Welebob, Emily ^a   Hartzema, Abraham G ^a,d   Stang, Paul ^a,e   Overhage, J Marc ^a,f  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse drug reactions; adverse reaction monitoring; data collection; drug monitoring; food and drug administration; legislation; medical records; pharmaceutical industry; pharmacovigilance; postmarketing surveillance

Indexed keywords

VACCINE;

ARTICLE; CONFIDENTIALITY; DATA BASE; DRUG INFUSION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDY; MEDICAL RECORD; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; OUTPATIENT; PATIENT CARE; PATIENT CODING; PHARMACOEPIDEMIOLOGY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; UNITED STATES;

EID: 77956455893     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/bf03256821     Document Type: Article

References (13)

1. FDA. The sentinel initiative: a national strategy for monitoring medical product safety 2008 [online]. Available from URL: http://www.fda.gov/Safety/ FDAsSentinelInitiative/ucm089474.htm [Accessed 2009 Nov 11]
2. Degge Group. Benefit-Risk Information for DruG Evaluations (B.R.I.D.G.E. TO DATA) 2009 [online]. Available from URL: http://www.bridgetodata. org/html/frameset.htm [Accessed 2009 Jun 7]
3. International Society of Pharmacoeconomics and Outcomes Research. ISPOR international digest of databases 2009 [online]. Available from URL: http://www.ispor.org/intl-databases/index.asp [Accessed 2009 Jun 7]
4. Strom B. Pharmacoepidemoilogy. Chicheseter: Wiley, 2005
5. Hartzema AG, Porta M, Tilson HH. Pharmacoepidemiology: an introduction. Cincinnati (OH): Harvey Whitney Books, 1999
6. Hartzema AG, Tilson HH, Chan K. Pharmacoepidemiology and therapeutic risk management. Cincinnati (OH): Harvey Whitney Books, 2008
7. Observational Medical Outcomes Partnership. Data assessment [online]. Available from URL: http://omop.fnih.org/DataAssessments [Accessed 2009 Feb 9]
8. Holbrook A, Grootendorst P, Willison D, et al. Can current electronic systems meet drug safety and effectiveness requirements? Proceedings of the AMIA 2005 Symposium; 2005 Oct 22-26; Washington DC. Bethesda (MD): American Medical Informatics Association, 2005: 335-339
9. Platt R, Madre L, Reynolds R, et al. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008; 17 (12): 1175-1182
10. Platt R, Wilson M, Chan KA, et al. The new sentinel network: improving the evidence of medical-product safety. N Engl J Med 2009; 361 (7): 645-647
11. Brown J, Lane K, Moore K, et al. Defining and evaluating possible database models to implement the FDA sentinel initiative [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2009-N-0192-0005. pdf [Accessed 2009 Aug 30]
12. Brown JS, Holmes JH, Shah K, et al. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care 2010; 48 (6 Suppl.): S45-51
13. Holmes JH, Brown J, Hennessy S, et al. Developing a distributed research network to conduct population-based studies and safety surveillance. AMIA Annu Symp Proc 2008; 973